Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A More Disciplined Teva Gets Lukewarm Reception From Street

Executive Summary

More organizational and strategic discipline, far greater selectivity in R&D and business development, and emphasis on profitable, not top-line, growth are at the core of the strategy put forth by Teva’s new management on Dec. 11. The reboot makes sense, given the company’s relentless focus on M&A over the past decade and its maturing generics businesses, so why are investors balking?

You may also be interested in...

Teva In Transition: Generics, Specialty And ‘The Space Between’

In an interview, President of Global R&D Michael Hayden talked about integrating Allergan generics, Teva’s late-stage specialty pipeline and its 17 new therapeutic entities, medicines that bridge generics and specialty medicine.

EMA Fells Two Orphan Drugs, Delays Teva’s Nerventra

The CHMP rejects AB Science’s Masiviera for pancreatic cancer, PTC Therapeutics’ Translarna for Duchenne muscular dystrophy and Teva’s Nerventra for MS.

Teva Struggles To Sell 2014 Guidance, Blue-Sky Estimates For NTE Program

The Israeli generics giant unveiled two sets of 2014 guidance, allowing for different levels of competition for Copaxone. But Wall Street sees the company slowing the pace of cost-cutting and providing overly optimistic revenue estimates for new therapeutic entities.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts